Efficacy of risperidone on positive features of schizophrenia.

Journal Article (Clinical Trial;Journal Article)

Dopaminergic hyperactivity mediated via D2 receptors is implicated in the etiology of positive symptoms of schizophrenia, but selective D2 antagonists provide imperfect therapy. This article describes a subanalysis of a trial of risperidone, a combined 5-HT2A/D2 antagonist, in 513 patients with DSM-III-R chronic schizophrenia. Risperidone at 2, 6, 10, and 16 mg/day was compared with placebo and haloperidol 20 mg/day. All doses of risperidone and the 20-mg dose of haloperidol were superior to placebo (mean change from baseline on the PANSS positive and general psychopathology subscales). The 6-mg dose of risperidone also produced significantly more improvement than haloperidol 20 mg. We conclude that risperidone is an effective drug for patients with positive features of schizophrenia.

Full Text

Duke Authors

Cited Authors

  • McEvoy, JP

Published Date

  • May 1994

Published In

Volume / Issue

  • 55 Suppl /

Start / End Page

  • 18 - 21

PubMed ID

  • 7520904

International Standard Serial Number (ISSN)

  • 0160-6689


  • eng

Conference Location

  • United States